{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T14:54:21Z","timestamp":1785596061133,"version":"3.56.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.intimp.2024.112090","type":"journal-article","created":{"date-parts":[[2024,4,18]],"date-time":"2024-04-18T03:31:14Z","timestamp":1713411074000},"page":"112090","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Influence of genetic polymorphisms on imatinib concentration and therapeutic response in patients with chronic-phase chronic myeloid leukemia"],"prefix":"10.1016","volume":"133","author":[{"given":"Fang","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3630-9002","authenticated-orcid":false,"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10314","key":"10.1016\/j.intimp.2024.112090_b0005","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1016\/S0140-6736(21)01204-6","article-title":"Chronic myeloid leukaemia","volume":"398","author":"Cortes","year":"2021","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.intimp.2024.112090_b0010","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1038\/leu.2015.152","article-title":"Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib","volume":"29","author":"Castagnetti","year":"2015","journal-title":"Leukemia"},{"issue":"2 Suppl 2","key":"10.1016\/j.intimp.2024.112090_b0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1053\/shem.2003.50033","article-title":"Chronic myeloid leukemia in the imatinib era","volume":"40","author":"Druker","year":"2003","journal-title":"Semin. Hematol."},{"issue":"12","key":"10.1016\/j.intimp.2024.112090_b0020","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1182\/bloodadvances.2019001329","article-title":"First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis","volume":"4","author":"Vener","year":"2020","journal-title":"Blood Adv."},{"issue":"23","key":"10.1016\/j.intimp.2024.112090_b0025","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.intimp.2024.112090_b0030","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12943-018-0780-6","article-title":"Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy","volume":"17","author":"Soverini","year":"2018","journal-title":"Mol. Cancer"},{"issue":"4","key":"10.1016\/j.intimp.2024.112090_b0035","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.ccell.2020.03.006","article-title":"Response and Resistance to BCR-ABL1-Targeted Therapies","volume":"37","author":"Braun","year":"2020","journal-title":"Cancer Cell"},{"issue":"9","key":"10.1016\/j.intimp.2024.112090_b0040","doi-asserted-by":"crossref","first-page":"879","DOI":"10.2165\/00003088-200544090-00001","article-title":"Clinical pharmacokinetics of imatinib","volume":"44","author":"Peng","year":"2005","journal-title":"Clin. Pharmacokinet."},{"issue":"3","key":"10.1016\/j.intimp.2024.112090_b0045","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18030603","article-title":"Genetic Polymorphisms Contribute to the Individual Variations of Imatinib Mesylate Plasma Levels and Adverse Reactions in Chinese GIST Patients","volume":"18","author":"Liu","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.intimp.2024.112090_b0050","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/ejh.12235","article-title":"OCT1 genetic variants are associated with long term outcomes in imatinib treated chronic myeloid leukemia patients","volume":"92","author":"Koren-Michowitz","year":"2014","journal-title":"Eur. J. Haematol."},{"issue":"7","key":"10.1016\/j.intimp.2024.112090_b0055","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1080\/17425255.2016.1184649","article-title":"Pharmacogenetics of tyrosine kinase inhibitors in gastrointestinal stromal tumor and chronic myeloid leukemia","volume":"12","author":"Ravegnini","year":"2016","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"4","key":"10.1016\/j.intimp.2024.112090_b0060","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.intimp.2024.112090_b0065","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.tips.2016.08.003","article-title":"Impact of Membrane Drug Transporters on Resistance to Small-Molecule Tyrosine Kinase Inhibitors","volume":"37","author":"Neul","year":"2016","journal-title":"Trends Pharmacol. Sci."},{"issue":"4","key":"10.1016\/j.intimp.2024.112090_b0070","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1007\/s11010-022-04376-6","article-title":"Transport and metabolism of tyrosine kinase inhibitors associated with chronic myeloid leukemia therapy: a review","volume":"477","author":"Kumar","year":"2022","journal-title":"Mol. Cell. Biochem."},{"issue":"4","key":"10.1016\/j.intimp.2024.112090_b0075","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/86882","article-title":"Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression","volume":"27","author":"Kuehl","year":"2001","journal-title":"Nat. Genet."},{"key":"10.1016\/j.intimp.2024.112090_b0080","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.phrs.2017.03.011","article-title":"Influence of MDR1 and CYP3A5 genetic polymorphisms on trough levels and therapeutic response of imatinib in newly diagnosed patients with chronic myeloid leukemia","volume":"120","author":"Harivenkatesh","year":"2017","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.intimp.2024.112090_b0085","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.phrs.2018.02.005","article-title":"Impact of SLC22A1 and CYP3A5 genotypes on imatinib response in chronic myeloid leukemia: A systematic review and meta-analysis","volume":"131","author":"Cargnin","year":"2018","journal-title":"Pharmacol. Res."},{"issue":"14","key":"10.1016\/j.intimp.2024.112090_b0090","doi-asserted-by":"crossref","first-page":"4750","DOI":"10.1158\/1078-0432.CCR-09-0145","article-title":"Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia","volume":"15","author":"Kim","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.intimp.2024.112090_b0095","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1093\/annonc\/mds532","article-title":"Influence of enzyme and transporter polymorphisms on trough imatinib concentration and clinical response in chronic myeloid leukemia patients","volume":"24","author":"Seong","year":"2013","journal-title":"Ann. Oncol."},{"issue":"11","key":"10.1016\/j.intimp.2024.112090_b0100","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/jhg.2010.98","article-title":"Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia","volume":"55","author":"Takahashi","year":"2010","journal-title":"J. Hum. Genet."},{"issue":"1","key":"10.1016\/j.intimp.2024.112090_b0105","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1177\/1078155209104380","article-title":"Clinical significance of ABCB1 genotyping in oncology","volume":"16","author":"Hamidovic","year":"2010","journal-title":"J. Oncol. Pharm. Pract."},{"issue":"10","key":"10.1016\/j.intimp.2024.112090_b0110","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.leukres.2015.07.006","article-title":"MRP1 and P-glycoprotein expression assays would be useful in the additional detection of treatment non-responders in CML patients without ABL1 mutation","volume":"39","author":"Park","year":"2015","journal-title":"Leuk. Res."},{"issue":"12","key":"10.1016\/j.intimp.2024.112090_b0115","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/j.leukres.2013.09.021","article-title":"Phosphorylated Crkl reduction levels are associated with the lowest P-glycoprotein activity levels in cells from chronic myeloid leukemia patients","volume":"37","author":"Vasconcelos","year":"2013","journal-title":"Leuk. Res."},{"issue":"3","key":"10.1016\/j.intimp.2024.112090_b0120","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/cyto.b.20580","article-title":"Variation of MDR proteins expression and activity levels according to clinical status and evolution of CML patients","volume":"80","author":"Vasconcelos","year":"2011","journal-title":"Cytometry B Clin. Cytom."},{"issue":"6","key":"10.1016\/j.intimp.2024.112090_b0125","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1182\/blood.V101.6.2368","article-title":"MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models","volume":"101","author":"Mahon","year":"2003","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.intimp.2024.112090_b0130","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1002\/(SICI)1097-0142(19990901)86:5<805::AID-CNCR16>3.0.CO;2-E","article-title":"Multidrug resistance protein expression in chronic myeloid leukemia: associations and significance","volume":"86","author":"Giles","year":"1999","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.intimp.2024.112090_b0135","doi-asserted-by":"crossref","first-page":"e0161470","DOI":"10.1371\/journal.pone.0161470","article-title":"ABCB1 Overexpression Is a Key Initiator of Resistance to Tyrosine Kinase Inhibitors in CML Cell Lines","volume":"11","author":"Eadie","year":"2016","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.intimp.2024.112090_b0140","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1097\/01.fpc.0000178311.02878.83","article-title":"Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability","volume":"15","author":"Wang","year":"2005","journal-title":"Pharmacogenet. Genomics"},{"issue":"5","key":"10.1016\/j.intimp.2024.112090_b0145","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1182\/blood-2008-03-147744","article-title":"Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia","volume":"112","author":"Dulucq","year":"2008","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.intimp.2024.112090_b0150","first-page":"244","article-title":"Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia","volume":"33","author":"Yamakawa","year":"2011","journal-title":"Ther. Drug Monit."},{"issue":"8","key":"10.1016\/j.intimp.2024.112090_b0155","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.leukres.2010.12.004","article-title":"Correlation between genetic polymorphisms of the hOCT1 and MDR1 genes and the response to imatinib in patients newly diagnosed with chronic-phase chronic myeloid leukemia","volume":"35","author":"Maffioli","year":"2011","journal-title":"Leuk. Res."},{"issue":"4","key":"10.1016\/j.intimp.2024.112090_b0160","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24043303","article-title":"Impact of ABCG2 and ABCB1 Polymorphisms on Imatinib Plasmatic Exposure: An Original Work and Meta-Analysis","volume":"24","author":"Dalle Fratte","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.intimp.2024.112090_b0165","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/nm0901-1028","article-title":"The ABC transporter Bcrp1\/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype","volume":"7","author":"Zhou","year":"2001","journal-title":"Nat. Med."},{"issue":"12","key":"10.1016\/j.intimp.2024.112090_b0170","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1124\/dmd.118.083030","article-title":"Polymorphisms of the Multidrug Pump ABCG2: A Systematic Review of Their Effect on Protein Expression, Function, and Drug Pharmacokinetics","volume":"46","author":"Heyes","year":"2018","journal-title":"Drug Metab. Dispos."},{"issue":"2","key":"10.1016\/j.intimp.2024.112090_b0175","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.clpt.2006.05.003","article-title":"Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib","volume":"80","author":"Gardner","year":"2006","journal-title":"Clin. Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.intimp.2024.112090_b0180","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.biopha.2014.01.009","article-title":"Association of genotypes and haplotypes of multi-drug transporter genes ABCB1 and ABCG2 with clinical response to imatinib mesylate in chronic myeloid leukemia patients","volume":"68","author":"Au","year":"2014","journal-title":"Biomed. Pharmacother."},{"issue":"24","key":"10.1016\/j.intimp.2024.112090_b0185","first-page":"7787","article-title":"Tailored tyrosine kinase inhibitor (TKI) treatment of chronic myeloid leukemia (CML) based on current evidence","volume":"25","author":"Ciftciler","year":"2021","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"issue":"5","key":"10.1016\/j.intimp.2024.112090_b0190","doi-asserted-by":"crossref","first-page":"731","DOI":"10.3324\/haematol.2011.045666","article-title":"Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial","volume":"97","author":"Guilhot","year":"2012","journal-title":"Haematologica"},{"issue":"Suppl 9","key":"10.1016\/j.intimp.2024.112090_b0195","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1002\/cncr.32751","article-title":"Correlations between imatinib plasma trough concentration and adverse reactions in Chinese patients with gastrointestinal stromal tumors","volume":"126","author":"Xia","year":"2020","journal-title":"Cancer"},{"issue":"22","key":"10.1016\/j.intimp.2024.112090_b0200","doi-asserted-by":"crossref","first-page":"3951","DOI":"10.1002\/cncr.34478","article-title":"Imatinib dose optimization based on therapeutic drug monitoring in Chinese patients with chronic-phase chronic myeloid leukemia","volume":"128","author":"Cheng","year":"2022","journal-title":"Cancer"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924006088?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576924006088?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T20:07:23Z","timestamp":1715630843000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576924006088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":40,"alternative-id":["S1567576924006088"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2024.112090","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Influence of genetic polymorphisms on imatinib concentration and therapeutic response in patients with chronic-phase chronic myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2024.112090","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"112090"}}